鉴定curaxin作为潜在的新疗法对JAK2 V617F突变患者的鉴定
Stella Pearson1, Rognvald Blance1, Fei Yan2,3
1Stem Cell and Leukaemia Proteomics Laboratory, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.
PloS one
|May 30, 2023
概括
研究人员将CBL0137确定为骨髓癌myelofibrosis的潜在治疗方法. 这种药物专门针对患者的癌症干细胞,提供了一种超越当前治疗方法的新方法.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 骨髓纤维化是一种骨髓扩散性瘤,导致显著的发病率和死亡率.
- 像鲁克索利提尼布这样的当前治疗方法的疗效有限,这凸显了对新疗法的需求.
- 药物再利用提供了一种有效的策略,以确定新的治疗候选者.
研究的目的:
- 通过重新分析蛋白质组数据来确定髓纤维化新型治疗点.
- 评估CBL0137在骨髓纤维化临床前模型中的疗效和作用机制.
主要方法:
- 重新分析蛋白质组数据以确定骨髓纤维化中乱的途径.
- 在初级患者样本和小鼠模型中评估CBL0137活性.
- 调查CBL0137对造血干细胞和祖细胞的作用机制.
主要成果:
- 鉴定出CBL0137是Jak2突变驱动的骨髓纤维化病的潜在药物.
- CBL0137首选向来自骨髓纤维化患者的CD34+干细胞和原生细胞.
- CBL0137在小鼠模型的骨髓扩散性瘤中减少了脊髓巨变和网状细胞数量.
结论:
- CBL0137在准髓纤维化驱动细胞方面表现出临床前的有效性.
- CBL0137的机制涉及针对FACT复合体,导致p53激活和NF-kB抑制.
- CBL0137代表了作为骨髓纤维化治疗的进一步发展的有希望的候选人.
相关概念视频
The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
NF-κB-dependent Signaling Pathway
7.5K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.5K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
205
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
205


